eculizumab | Eculizumab

Keyword	CPC	PCC	Volume	Score	Length of keyword
eculizumab	1.46	0.7	4149	35	10

Keyword	CPC	PCC	Volume	Score
eculizumab	0.24	0.6	4612	78
eculizumab cost	0.94	0.8	557	80
eculizumab package insert	0.07	0.9	5032	55
eculizumab moa	1.18	0.4	5805	80
eculizumab mechanism of action	1.03	1	9535	18
eculizumab rems	0.15	0.3	4326	28
eculizumab soliris	0.98	0.4	3872	60
eculizumab brand name	0.55	0.3	7552	16
eculizumab biosimilar	1.77	0.1	7647	10
eculizumab myasthenia gravis	0.39	0.9	5581	63
eculizumab pnh	1.58	0.3	6285	15
eculizumab spc	0.69	0.8	9183	76
eculizumab fda label	0.64	0.4	7751	28
eculizumab nmosd	0.16	0.5	1031	89
eculizumab ahus	0.54	0.5	7248	84
eculizumab precio	0.56	0.2	6807	91
eculizumab side effects	1.43	0.3	1300	34
eculizumab infusion	0.28	0.2	1842	92
eculizumab injection	1.36	0.1	6820	6
eculizumab ficha tecnica	1.25	0.4	8880	68
eculizumab fachinformation	0.01	0.7	6139	46
eculizumab prescribing information	1.15	0.6	5793	8

Search Results related to eculizumab on Search Engine

Eculizumab - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Eculizumab

WebEculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and …

DA: 70 PA: 68 MOZ Rank: 18

SOLIRIS® (eculizumab) Home | HCP Site
solirisnmosd-hcp.com

https://solirisnmosd-hcp.com/

WebSOLIRIS ® (eculizumab) is the first FDA-approved complement inhibitor indicated for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). 1

DA: 99 PA: 59 MOZ Rank: 100

Eculizumab Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/eculizumab.html

WebWhat is eculizumab? Eculizumab is used in adults to treat myasthenia gravis or neuromyelitis optica spectrum disorder. Eculizumab is also used to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria.

DA: 31 PA: 71 MOZ Rank: 46

Eculizumab: Uses, Interactions, Mechanism of Action | DrugBank …
drugbank.com

https://go.drugbank.com/drugs/DB01257

WebMay 16, 2007 · Eculizumab is a monoclonal antibody that prevents the activation of terminal complement in some autoimmune conditions. 7,1,2 Eculizumab has a long duration of action. 7 Patients taking this medication should be vaccinated against Neisseria meningiditis as serious meningococcal infections have occurred in the past. 7,2

DA: 88 PA: 19 MOZ Rank: 85

FDA approves first treatment for neuromyelitis optica spectrum …
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-neuromyelitis-optica-spectrum-disorder-rare-autoimmune-disease-central

WebJune 27, 2019. The U.S. Food and Drug Administration today approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult...

DA: 39 PA: 49 MOZ Rank: 7

Soliris® (eculizumab) | Alexion
alexion.com

https://alexion.com/en/our-medicines/medicines/soliris

WebSOLIRIS is indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti ...

DA: 27 PA: 90 MOZ Rank: 70

Eculizumab Injection: MedlinePlus Drug Information
medlineplus.gov

https://medlineplus.gov/druginfo/meds/a612024.html

WebEculizumab injection is used to treat paroxysmal nocturnal hemoglobinuria (PNH: a type of anemia in which too many red blood cells are broken down in the body, so there are not enough healthy cells to bring oxygen to all parts of the body).

DA: 4 PA: 26 MOZ Rank: 78

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa061648

WebSep 21, 2006 · Eculizumab (Soliris, Alexion Pharmaceuticals) is a humanized monoclonal antibody directed against the terminal complement protein C5. 13 In a preliminary, 12-week, open-label clinical study...

DA: 61 PA: 26 MOZ Rank: 76

Eculizumab (Soliris) for Neuromyelitis Optica Spectrum Disorder
clevelandclinic.org

https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/eculizumab

WebEculizumab is a humanized monoclonal antibody that inhibits the terminal complement protein C5 to prevent its cleavage into C5a and C5b. The exact mechanism for its efficacy in NMOSD is unknown, but is believed to be related to inhibition of the formation of the membrane attack complex mediated by C5b. Q.

DA: 67 PA: 60 MOZ Rank: 80

Terminal Complement Inhibitor Eculizumab in Atypical …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1208981

WebJun 6, 2013 · Eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is a humanized monoclonal antibody that binds with high affinity to the human C5 complement protein and blocks the...

DA: 18 PA: 65 MOZ Rank: 48